AKT1 and neoplasm: Importantly, the phospho-PRASTHR246 epitope was more stable than the phospho-AKTSER473 epitope commonly used for identifying tumours with AKT pathway activation, suggesting that this biomarker might be more suitable for clinical evaluation of PI3K pathway inhibition.